After long decades of considering KRAS as an elusive target in NSCLC, sotorasib and adagrasib as well as emerging KRAS-mutant targeted treatments constitute an unprecedent improvement to efficiently target KRAS-mutant NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.